Literature DB >> 20645673

Topical delivery for the treatment of psoriasis.

Amitava Mitra1, Yunhui Wu.   

Abstract

IMPORTANCE OF THE FIELD: Psoriasis is one of the most common human skin diseases. Topical therapy forms the cornerstone in the management of mild-to-moderate psoriasis. Topical therapies are also used as adjunctive to systemic therapy in moderate and severe forms of the disease. AREAS COVERED IN THIS REVIEW: In this review, an overview of psoriasis pathogenesis, new topical medications for psoriasis, new targets and molecules, combination topical therapies and combination of topical and phototherapy is provided. Over the past decade several efficacious and acceptable treatment options have emerged from the age-old therapies. The development of sophisticated formulation options has led to an enhancement in the rate and extent of drug delivery across the skin, increasing therapeutic value and improving patient compliance. WHAT THE READER WILL GAIN: Readers will learn about monotherapy and combination topical products as well as new topical drug delivery technology to achieve optimal clinical outcomes. This review will highlight the need to generate more dermal pharmacokinetic data for better understanding of the impact of formulation change on skin pharmacokinetics to help design improved topical drug delivery systems. TAKE HOME MESSAGE: New topical formulations have the potential to achieve better efficacy with improved safety profile.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645673     DOI: 10.1517/17425247.2010.503953

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  3 in total

1.  Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis.

Authors:  Meera Gujjar; Jack Arbiser; Rick Coulon; Ajay K Banga
Journal:  J Drug Target       Date:  2015-09-22       Impact factor: 5.121

2.  Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone.

Authors:  Parinbhai Shah; Benjamin Goodyear; Nirali Dholaria; Vinam Puri; Bozena Michniak-Kohn
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

3.  Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966.

Authors:  Maria Lapteva; Sergio Del Río-Sancho; Eric Wu; W Shawn Carbonell; Christof Böhler; Yogeshvar N Kalia
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.